Immunome (IMNM) Revenue & Revenue Breakdown
Immunome Revenue Highlights
Latest Revenue (Y)
$14.02M
Latest Revenue (Q)
$2.36M
Immunome Revenue by Period
Immunome Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $14.02M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Immunome generated $14.02M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Immunome Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.36M | 129.74% |
| 2024-03-31 | $1.03M | -73.11% |
| 2023-12-31 | $3.83M | 7.32% |
| 2023-09-30 | $3.56M | -16.37% |
| 2023-06-30 | $4.26M | 80.33% |
| 2023-03-31 | $2.36M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Immunome generated $2.36M in revenue during Q2 2024, up 129.74% compared to the previous quarter, and up 100.00% compared to the same period a year ago.
Immunome Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAG | Adagene | $18.11M | $833.34K |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| IMNM | Immunome | $14.02M | $2.36M |
| IKNA | Ikena Oncology | $9.16M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MNOV | MediciNova | $1.00M | - |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| GANX | Gain Therapeutics | $55.18K | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| INAB | IN8bio | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| CELC | Celcuity | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| LTRN | Lantern Pharma | - | - |
| CSBR | Champions Oncology | - | $12.02M |
IMNM Revenue FAQ
What is Immunome’s yearly revenue?
Immunome's yearly revenue for 2023 was $14.02M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. IMNM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Immunome’s quarterly revenue?
Immunome's quarterly revenue for Q2 2024 was $2.36M, a 129.74% increase from the previous quarter (Q1 2024), and a -44.55% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.03M, a -73.11% decrease from the previous quarter (Q4 2023), and a -56.47% decrease year-over-year (Q1 2023). IMNM's quarterly revenue for Q4 2023 was $3.83M, a 7.32% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Immunome’s revenue growth rate?
Immunome's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.